{"id":"enoxolone","rwe":[{"pmid":"41797801","year":"2026","title":"Integrating network pharmacology, molecular docking and dynamics simulation to decipher the antipyretic mechanisms of Xiaochaihu granules.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"},{"pmid":"41155634","year":"2025","title":"Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with Enoxolone.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40993708","year":"2025","title":"Enoxolone pharmacokinetics, tissue distribution, and residue depletion in largemouth bass (Micropterus salmoides).","finding":"","journal":"BMC veterinary research","studyType":"Clinical Study"},{"pmid":"40732228","year":"2025","title":"Optimized Enoxolone-Loaded Microsponges for Drug Delivery: A Design of Experiments Approach.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40602502","year":"2025","title":"Core effective components identifying strategy of Xingbei Zhike granule: integrating multi-component quantification, tissue distribution, oral bioavailability, and antitussive effect.","finding":"","journal":"Journal of ethnopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"enoxolone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Corticosteroid 11-beta-dehydrogenase isozyme 2","category":"target"},{"label":"HSD11B2","category":"gene"},{"label":"HSD11B1","category":"gene"},{"label":"PRKCH","category":"gene"},{"label":"D03AX10","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"biosone","offLabel":[],"synonyms":["enoxolone","uralenic acid","arthrodont","biosone","glycyrrhetic acid","glycyrrhetin","glycyrrhetinic acid","subglycyrrhelinic acid"],"timeline":[],"approvals":[],"brandName":"Biosone","ecosystem":[],"mechanism":{"target":"High mobility group protein B1, Aldo-keto reductase family 1 member B10, Cocaine esterase","targets":[{"gene":"HSD11B2","source":"DrugCentral","target":"Corticosteroid 11-beta-dehydrogenase isozyme 2","protein":"Corticosteroid 11-beta-dehydrogenase isozyme 2"},{"gene":"HSD11B1","source":"DrugCentral","target":"Corticosteroid 11-beta-dehydrogenase isozyme 1","protein":"Corticosteroid 11-beta-dehydrogenase isozyme 1"},{"gene":"PRKCH","source":"DrugCentral","target":"Protein kinase C eta type","protein":"Protein kinase C eta type"},{"gene":"AKR1B10","source":"DrugCentral","target":"Aldo-keto reductase family 1 member B10","protein":"Aldo-keto reductase family 1 member B10"},{"gene":"PTPN11","source":"DrugCentral","target":"Tyrosine-protein phosphatase non-receptor type 11","protein":"Tyrosine-protein phosphatase non-receptor type 11"},{"gene":"CES1","source":"DrugCentral","target":"Liver carboxylesterase 1","protein":"Liver carboxylesterase 1"},{"gene":"ALOX5","source":"DrugCentral","target":"Arachidonate 5-lipoxygenase","protein":"Arachidonate 5-lipoxygenase"},{"gene":"PTPN1","source":"DrugCentral","target":"Tyrosine-protein phosphatase non-receptor type 1","protein":"Tyrosine-protein phosphatase non-receptor type 1"},{"gene":"PTPN6","source":"DrugCentral","target":"Protein-tyrosine phosphatase 1C","protein":"Tyrosine-protein phosphatase non-receptor type 6"},{"gene":"CES2","source":"DrugCentral","target":"Cocaine esterase","protein":"Cocaine esterase"}],"modality":"Small Molecule","drugClass":"enoxolone","explanation":"Think of cortisol as a fire that can get out of control and cause damage. Cortisol is converted into cortisone, which is a less active form, by an enzyme called 11-beta-dehydrogenase. Biosone blocks this enzyme, so cortisol stays active and can't cause as much inflammation.","oneSentence":"Biosone works by blocking the enzyme that converts cortisol into cortisone, reducing inflammation.","technicalDetail":"Biosone (ENOXOLONE) is a potent inhibitor of 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2), an enzyme that converts cortisol into cortisone in various tissues, including the kidneys and colon."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3178","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ENOXOLONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ENOXOLONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:00:51.094724","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:12.360236+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dexpanthenol","drugSlug":"dexpanthenol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"calcium pantothenate","drugSlug":"calcium-pantothenate","fdaApproval":"1993-12-29","relationship":"same-class"},{"drugName":"hyaluronic acid","drugSlug":"hyaluronic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"becaplermin","drugSlug":"becaplermin","fdaApproval":"1997-12-16","relationship":"same-class"},{"drugName":"trolamine","drugSlug":"trolamine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"enoxolone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dexpanthenol","brandName":"dexpanthenol","genericName":"dexpanthenol","approvalYear":"1953","relationship":"same-class"},{"drugId":"calcium-pantothenate","brandName":"calcium pantothenate","genericName":"calcium pantothenate","approvalYear":"1993","relationship":"same-class"},{"drugId":"hyaluronic-acid","brandName":"hyaluronic acid","genericName":"hyaluronic acid","approvalYear":"","relationship":"same-class"},{"drugId":"becaplermin","brandName":"becaplermin","genericName":"becaplermin","approvalYear":"1997","relationship":"same-class"},{"drugId":"trolamine","brandName":"trolamine","genericName":"trolamine","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07286487","phase":"NA","title":"Glycyrrhetinic Acid and Acute Irritant Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of Split, School of Medicine","startDate":"2026-03-01","conditions":["Irritant Contact Dermatitis"],"enrollment":30,"completionDate":"2027-04-25"},{"nctId":"NCT05570110","phase":"PHASE1,PHASE2","title":"Enoxolone in Major Depression - Biomarker-outcome Relationship","status":"RECRUITING","sponsor":"Philipps University Marburg","startDate":"2022-09-23","conditions":["Unipolar Depression"],"enrollment":80,"completionDate":"2026-06"},{"nctId":"NCT07064889","phase":"PHASE2","title":"The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-30","conditions":["Immune Thrombocytopenia"],"enrollment":132,"completionDate":"2027-12-30"},{"nctId":"NCT05987722","phase":"NA","title":"Effectiveness of Enoxolone on Oral Conditions of Patients With Periodontal Surgery","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2021-07-30","conditions":["Periodontal Surgery"],"enrollment":27,"completionDate":"2022-12-08"},{"nctId":"NCT04593758","phase":"PHASE1,PHASE2","title":"To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue","status":"COMPLETED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2021-09-01","conditions":["Sarcoma, Clear Cell"],"enrollment":16,"completionDate":"2023-03-09"},{"nctId":"NCT01649947","phase":"PHASE2","title":"Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2011-12-23","conditions":["Non-small Cell Lung Cancer","Advanced Non-small Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer"],"enrollment":32,"completionDate":"2015-06-30"},{"nctId":"NCT04217148","phase":"PHASE2","title":"The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2020-01-01","conditions":["Immune Thrombocytopenia"],"enrollment":132,"completionDate":"2020-06-30"},{"nctId":"NCT03998982","phase":"PHASE4","title":"Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-06-25","conditions":["Immune Thrombocytopenia"],"enrollment":30,"completionDate":"2021-06-10"},{"nctId":"NCT03874949","phase":"NA","title":"Pain After Root Canal Obturation With Sealer Containing or Not 1% Enoxolone","status":"COMPLETED","sponsor":"ACTEON Group","startDate":"2019-04-02","conditions":["Root Canal Obturation"],"enrollment":95,"completionDate":"2019-08-20"},{"nctId":"NCT02387710","phase":"PHASE2","title":"Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-03","conditions":["Sleep Apnea, Obstructive"],"enrollment":18,"completionDate":"2016-07"},{"nctId":"NCT01209507","phase":"","title":"Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-02","conditions":["Adrenal Suppression"],"enrollment":19,"completionDate":"2015-11"},{"nctId":"NCT00759525","phase":"PHASE2,PHASE3","title":"The Role of Mineralocorticoid Receptors in Vascular Function","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2002-02","conditions":["Apparent Mineralocorticoid Excess (AME)"],"enrollment":15,"completionDate":"2009-09"},{"nctId":"NCT02750917","phase":"PHASE3","title":"Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Foisor Orthopedics Clinical Hospital","startDate":"2014-09","conditions":["Postoperative Pain"],"enrollment":120,"completionDate":"2015-03"},{"nctId":"NCT01971606","phase":"PHASE4","title":"Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2007-10","conditions":["A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB."],"enrollment":234,"completionDate":"2013-03"},{"nctId":"NCT00540436","phase":"PHASE2","title":"Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":["Hypertension, Pulmonary"],"enrollment":25,"completionDate":"2009-01"},{"nctId":"NCT00384384","phase":"PHASE2","title":"Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-08","conditions":["End Stage Renal Disease"],"enrollment":24,"completionDate":"2007-04"},{"nctId":"NCT00454298","phase":"PHASE1","title":"Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-05","conditions":["Osteoarthritis"],"enrollment":2,"completionDate":"2008-03"},{"nctId":"NCT00672373","phase":"PHASE3","title":"Extract of Ginkgo Biloba and Tardive Dyskinesia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2006-12","conditions":["Tardive Dyskinesia","Schizophrenia"],"enrollment":157,"completionDate":"2007-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166340","NDDF":"005620","UNII":"P540XA09DR","CHEBI":"CHEBI:30853","INN_ID":"1794","RXNORM":"1311506","UMLSCUI":"C0017986","ChEMBL_ID":"CHEMBL230006","KEGG_DRUG":"D00156","DRUGBANK_ID":"DB13089","PDB_CHEM_ID":"CBW","PUBCHEM_CID":"10114","SNOMEDCT_US":"414356009","IUPHAR_LIGAND_ID":"11264","MESH_DESCRIPTOR_UI":"D006034"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":47,"therapeuticAreas":["Nephrology"],"atcClassification":{"source":"DrugCentral","atcCode":"D03AX10","allCodes":["D03AX10"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41797801","title":"Integrating network pharmacology, molecular docking and dynamics simulation to decipher the antipyretic mechanisms of Xiaochaihu granules.","journal":"Frontiers in medicine"},{"date":"2025 Oct 10","pmid":"41155634","title":"Discovery of Personalized Treatment for Immuno-Metabolic Depression-Focus on 11beta Hydroxysteroid Dehydrogenase Type 2 (11betaHSD2) and Toll-like Receptor 4 (TLR4) Inhibition with Enoxolone.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Sep 24","pmid":"40993708","title":"Enoxolone pharmacokinetics, tissue distribution, and residue depletion in largemouth bass (Micropterus salmoides).","journal":"BMC veterinary research"},{"date":"2025 Jun 21","pmid":"40732228","title":"Optimized Enoxolone-Loaded Microsponges for Drug Delivery: A Design of Experiments Approach.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Aug 29","pmid":"40602502","title":"Core effective components identifying strategy of Xingbei Zhike granule: integrating multi-component quantification, tissue distribution, oral bioavailability, and antitussive effect.","journal":"Journal of ethnopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biosone (ENOXOLONE) is a small molecule enoxolone that targets corticosteroid 11-beta-dehydrogenase isozyme 2. It is not FDA-approved, and its commercial status is unknown. Biosone works by inhibiting the enzyme responsible for converting cortisol into cortisone, thereby reducing inflammation. It is being developed for potential use in treating various inflammatory conditions, but its exact indications and safety profile are not well established. Further research is needed to determine its efficacy and safety in humans.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:12.360236+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}